Please fill in the form with your username, your password will be send to your registered e-mail.
* Mandatory fields
Website dedicated to help patients, their family and friends about the cancer immunotherapeutic approach in an easy-to-understand format.
Website providing information about the now recruiting Non-Small Cell Lung Cancer phase III clinical study
This section describes the potential of MAGE-A3 ASCI in Non-Small Cell Lung Cancer (NSCLC).
NSCLC is the most common type of lung cancer, and is associated with poor outcomes.
MAGE-A3 is a genuine cancer-specific antigen that is present in 35-50% of patients with NSCLC. The expression of MAGE-A3 has been associated with advanced disease and poor outcome. This adds further support to the use of MAGE-A3 antigen in the ASCI treatment of NSCLC.
If this is your first time at this site, please click here to register.
Register now
For legal reasons, this page is intended solely for healthcare professionals. This is why we ask you to register.
© 2001 - 2008 GlaxoSmithKline plc. All rights reserved.